Giancarlo Marone

TL;DR: Increasing evidence in certain experimental models indicates that targeting mast cells and/or their mediators represent a potential therapeutic target in cancer.

TL;DR: The mechanisms of the most prominent checkpoint inhibitors are described, specifically ipilimumab (anti-CTLA-4, the godfather of checkpoint inhibitors) patient and monoclonal antibodies targeting PD-1 and PD-L1 (eg, atezolizumab).

TL;DR: Increasing evidence in experimental models indicates that activation/recruitment of eosinophils could represent a new therapeutic strategy for certain tumors (e.g., melanoma) and many unanswered questions should be addressed before it is understood whether eos inophils are an ally, adversary or neutral bystanders in different types of human cancers.

TL;DR: Emerging evidence indicates that TSLP is also involved in chronic inflammatory and autoimmune diseases and autoimmune disorders and several cancers, and first-in-class human monoclonal antibody Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has shown safety and efficacy.

TL;DR: In this paper, the authors have identified multiple mechanisms of CTX caused by antineoplastic drugs, including reactive oxygen species (ROS) and reactive nitrogen species RNS.